Results 141 to 150 of about 25,256 (244)

Preliminary evidence of long‐term safety and effectiveness of anti‐CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52‐week follow‐up retrospective study

Epilepsia Open, EarlyView.
Abstract Migraine and epilepsy frequently coexist, but evidence on the safety of calcitonin gene‐related peptide (CGRP)‐targeting therapies in people with epilepsy is lacking. We evaluated long‐term migraine and epilepsy outcomes in a real‐world multicenter retrospective cohort of adults with comorbid migraine and epilepsy treated with anti‐CGRP ...
Marina Romozzi, Andrea Burgalassi, Francesco Ceriello, Pietro Martino, Giuliano Sette, Francesca Pistoia, Fabio Placidi, Diego Centonze, Luca Pani, Jacopo Canonichesi, Catello Vollono, Paolo Calabresi, Maria Albanese, Luigi Francesco Iannone   +13 more
wiley   +1 more source

Risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis. [PDF]

J Neurol Neurosurg Psychiatry
Razaz N, Soderling J, Tomson T, Werenberg Dreier J, Christensen J, Bjørk MH, Igland J.   +6 more
europepmc   +1 more source

Reversal of refractory epilepsy in an adult with GAMT deficiency: A case report and comparative literature review

Epilepsia Open, EarlyView.
Abstract Objective Guanidinoacetate methyltransferase (GAMT) deficiency is a rare autosomal recessive creatine biosynthesis disorder. Reports specifically focusing on adult patients remain scarce. Methods We report a 52‐year‐old female (the oldest documented case of GAMT deficiency to date) presenting with severe intellectual disability, refractory ...
Wei‐Hung Sung, Hsi Chen, Che‐Wei Hsu, Meng‐Han Tsai   +3 more
wiley   +1 more source

Levetiracetam for Seizure Prophylaxis after Traumatic Brain Injury: A Severity-Stratified Cohort Study of 51,000 Patients. [PDF]

Ann Neurol
Thorman IB, Sacknovitz A, Li AG, Malhotra A, McGoldrick PE, Schubert MC, Muh CR, Wolf SM, Rosenberg JB, Bauerschmidt A, Mayer SA, Gandhi CD, Al-Mufti F.   +12 more
europepmc   +1 more source

Research progress on the role of inflammatory mediators in the pathogenesis of epilepsy

Ibrain, Volume 11, Issue 1, Page 44-58, Spring 2025.
In the central nervous system, activated immune cells lead to the overproduction of inflammatory mediators through the corresponding signal pathway. Under the stimulation of inflammatory factors, neuroinflammation ultimately occurs. Overexpression of inflammatory mediators and activated immunocytes plays an important role in the emergence and ...
Yue Yu, Fei‐Ji Sun
wiley   +1 more source

Comparative Neuropharmacological Effects of Antiseizure Drugs on Cultured Myenteric and Dorsal Root Ganglion Neurons. [PDF]

Pharmaceuticals (Basel)
Subbotin A, Volk HA, Meller S, Mazzuoli-Weber G, Elfers K.   +4 more
europepmc   +1 more source

Effects of Clopidogrel on the Anticonvulsant Efficacy of Valproic Acid and Levetiracetam in a PTZ-Induced Seizure Model. [PDF]

Int J Mol Sci
Özdemir S, Bolayir E, Şahin İnan ZD.
europepmc   +1 more source

A real‐world analysis of AI chatbot performance for medicines information enquiries

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background The provision of medicines information (MI) services requires interpretation and clinical judgement of complex scenarios by pharmacists. To date, few studies have assessed the performance of artificial intelligence (AI) chatbots to assist pharmacists providing MI advice.
Duncan Yorkston, Tracey Borrie, Paul Chin   +2 more
wiley   +1 more source

Trends in Use of Antiseizure Medicines in Women With Epilepsy in Pregnancy During 2018-2023 in an Irish Maternity Hospital: A Cohort Study. [PDF]

Obstet Gynecol Int
Devin JE, O'Shaughnessy F, Cleary BJ, Donnelly JC, Maher N.   +4 more
europepmc   +1 more source

Placebo Effect in Levodopa‐Induced Dyskinesia: A Systematic Review and Meta‐Analysis

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Levodopa‐induced dyskinesia (LID) is a complication of Parkinson's disease (PD) treatment. While the placebo effect is a known component in PD clinical trials, its specific magnitude in the context of LID is not well characterized.
Luiz Vinicius Silva Correa, Alexandre Martins do Nascimento, Bruno Lopes Santos‐Lobato, Henry Mauricio Chaparro‐Solano, Ignacio Fernandez Mata, Vitor Tumas   +5 more
wiley   +1 more source